Tilray and the University of British Columbia last year completed a small study on the effect of vaporized cannabis in patients with chronic PTSD, according to a clinical trial record updated in March 2020.
First announced in November 2014, the study started recruiting in February 2017 and appears to have been suspended by September 2019. It is not clear if it resumed and is now reported as completed.
According to clinical records, six people enrolled in the study. The anticipated number was 42.
In May 2018, the study’s principal researcher and clinical psychologist at the University of British Columbia, Zachary Walsh, was interviewed by the Globe and Mail.
The article referred to the study as “the country’s first randomized, controlled trial to evaluate the impact of medicinal cannabis on PTSD.”
Dr. Walsh was involved in a study that evaluated MDMA as a treatment for PTSD.